126
|
Agra Bermejo R, Cordero A, García-Acuña JM, Gómez Otero I, Varela Román A, Martínez Á, Álvarez Rodríguez L, Abou-Jokh C, Rodríguez-Mañero M, Cid Álvarez B, López-Palop R, Carrillo P, González-Juanatey JR. Determinants and Prognostic Impact of Heart Failure and Left Ventricular Ejection Fraction in Acute Coronary Syndrome Settings. ACTA ACUST UNITED AC 2017; 71:820-828. [PMID: 29249471 DOI: 10.1016/j.rec.2017.10.030] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2017] [Accepted: 10/19/2017] [Indexed: 12/20/2022]
Abstract
INTRODUCTION AND OBJECTIVES Contemporary data on the incidence and prognosis of heart failure (HF) and the influence of left ventricular ejection fraction (LVEF) in the setting of acute coronary syndrome (ACS) are scant. The aim of this study was to examine the relationship between LVEF and HF with long-term prognosis in a cohort of patients with ACS. METHODS This is a retrospective observational study of 6208 patients consecutively admitted for ACS to 2 different Spanish hospitals. Baseline characteristics were examined and a follow-up period was established for registration of death and HF rehospitalization as the primary endpoint. RESULTS Among the study participants, 5064 had ACS without HF during hospitalization: 290 (5.8%) had LVEF<40%, 540 (10.6%) LVEF 40% to 49%, and 4234 (83.6%) LVEF ≥ 50%. The remaining 1144 patients developed HF in the acute phase: 395 (34.6%) had LVEF<40%, 251 (21.9%) LVEF 40% to 49%, and 498 (43.5%) LVEF ≥ 50%. Patients with LVEF 40% to 49% had a demographic and clinical profile with intermediate features between the LVEF <40% and LVEF ≥ 50% groups. Kaplan-Meier curves showed that mortality and HF readmissions were statistically different depending on LVEF in the non-HF group but not in the HF group. Left ventricular ejection fraction ≥ 50% was an independent prognostic factor in the non-HF group only. CONCLUSIONS In ACS, long-term prognosis is considerably worse in patients who develop HF during hospitalization than in patients without HF, irrespective of LVEF. This parameter is a strong prognostic predictor only in patients without HF.
Collapse
|
127
|
García-Blas S, Bonanad C, Llàcer P, Ventura S, Núñez JM, Sánchez R, Chamorro C, Fácila L, de la Espriella R, Vaquer JM, Cordero A, Roqué M, Ortiz V, Racugno P, Bodí V, Valero E, Santas E, Moreno MDC, Miñana G, Carratalá A, Bondanza L, Payá A, Cardells I, Heredia R, Pellicer M, Valls G, Palau P, Bosch MJ, Raso R, Sánchez A, Bertomeu-González V, Bertomeu-Martínez V, Montagud-Balaguer V, Albiach-Montañana C, Pendás-Meneau J, Marcaida G, Cervantes-García S, San Antonio R, de Mingo E, Chorro FJ, Sanchis J, Núñez J. Diuretic Strategies in Acute Heart Failure and Renal Dysfunction: Conventional vs Carbohydrate Antigen 125-guided Strategy. Clinical Trial Design. ACTA ACUST UNITED AC 2017; 70:1067-1073. [DOI: 10.1016/j.rec.2017.02.028] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2016] [Accepted: 02/09/2017] [Indexed: 01/24/2023]
|
128
|
García-Blas S, Bonanad C, Llàcer P, Ventura S, Núñez JM, Sánchez R, Chamorro C, Fácila L, de la Espriella R, Vaquer JM, Cordero A, Roqué M, Ortiz V, Racugno P, Bodí V, Valero E, Santas E, Moreno MDC, Miñana G, Carratalá A, Bondanza L, Payá A, Cardells I, Heredia R, Pellicer M, Valls G, Palau P, Bosch MJ, Raso R, Sánchez A, Bertomeu-González V, Bertomeu-Martínez V, Montagud-Balaguer V, Albiach-Montañana C, Pendás-Meneau J, Marcaida G, Cervantes-García S, San Antonio R, de Mingo E, Chorro FJ, Sanchis J, Núñez J. Estrategias diuréticas en insuficiencia cardiaca aguda con disfunción renal: terapia convencional frente a guiada por el antígeno carbohidrato 125. Diseño de ensayo clínico. Rev Esp Cardiol 2017. [DOI: 10.1016/j.recesp.2017.02.011] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
129
|
Delgado-Vargas B, Medina M, Polo R, Lloris A, Vaca M, Pérez C, Cordero A, Cobeta I. Cochlear obliteration following a translabyrinthine approach and its implications in cochlear implantation. ACTA ACUST UNITED AC 2017; 38:56-60. [PMID: 29187758 DOI: 10.14639/0392-100x-1218] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2016] [Accepted: 06/06/2017] [Indexed: 11/23/2022]
Abstract
The most frequent sequelae following a translabyrinthine approach for vestibular schwannoma resection is complete hearing loss on the affected side. Such patients could benefit from a cochlear implant, provided that two essential requisites are met before surgery: a preserved cochlear nerve and a patent cochlea to accommodate the electrode array. The goal of our study is to determine the prevalence and extent of cochlear ossification following a translabyrinthine approach. Postoperative MRI of 41 patients were retrospectively reviewed. Patients were classified according to the degree of cochlear obliteration into three groups (patent cochlea, partially obliterated cochlea and totally obliterated cochlea). The interval between surgery and the first MRI was studied as well as its relationship with the rate of cochlear ossification. At first postoperative MRI (mean interval of 20 months), 78% of patients showed some degree of cochlear ossification. Differences were found in the time interval between surgery and first MRI for each group, showing a smaller interval of time the patent cochlea group (p > 0.05). When MRI was performed before the first year after surgery, a larger rate of patent cochlea was found (p > 0.05). The present study suggests that cochlear ossification is a time-depending process, whose grounds are still to be defined.
Collapse
|
130
|
Orozco-Beltran D, Gil-Guillen VF, Redon J, Martin-Moreno JM, Pallares-Carratala V, Navarro-Perez J, Valls-Roca F, Sanchis-Domenech C, Fernandez-Gimenez A, Perez-Navarro A, Bertomeu-Martinez V, Bertomeu-Gonzalez V, Cordero A, Pascual de la Torre M, Trillo JL, Carratala-Munuera C, Pita-Fernandez S, Uso R, Durazo-Arvizu R, Cooper R, Sanz G, Castellano JM, Ascaso JF, Carmena R, Tellez-Plaza M. Lipid profile, cardiovascular disease and mortality in a Mediterranean high-risk population: The ESCARVAL-RISK study. PLoS One 2017; 12:e0186196. [PMID: 29045483 PMCID: PMC5646809 DOI: 10.1371/journal.pone.0186196] [Citation(s) in RCA: 56] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2017] [Accepted: 09/27/2017] [Indexed: 12/17/2022] Open
Abstract
INTRODUCTION The potential impact of targeting different components of an adverse lipid profile in populations with multiple cardiovascular risk factors is not completely clear. This study aims to assess the association between different components of the standard lipid profile with all-cause mortality and hospitalization due to cardiovascular events in a high-risk population. METHODS This prospective registry included high risk adults over 30 years old free of cardiovascular disease (2008-2012). Diagnosis of hypertension, dyslipidemia or diabetes mellitus was inclusion criterion. Lipid biomarkers were evaluated. Primary endpoints were all-cause mortality and hospital admission due to coronary heart disease or stroke. We estimated adjusted rate ratios (aRR), absolute risk differences and population attributable risk associated with adverse lipid profiles. RESULTS 51,462 subjects were included with a mean age of 62.6 years (47.6% men). During an average follow-up of 3.2 years, 919 deaths, 1666 hospitalizations for coronary heart disease and 1510 hospitalizations for stroke were recorded. The parameters that showed an increased rate for total mortality, coronary heart disease and stroke hospitalization were, respectively, low HDL-Cholesterol: aRR 1.25, 1.29 and 1.23; high Total/HDL-Cholesterol: aRR 1.22, 1.38 and 1.25; and high Triglycerides/HDL-Cholesterol: aRR 1.21, 1.30, 1.09. The parameters that showed highest population attributable risk (%) were, respectively, low HDL-Cholesterol: 7.70, 11.42, 8.40; high Total/HDL-Cholesterol: 6.55, 12.47, 8.73; and high Triglycerides/HDL-Cholesterol: 8.94, 15.09, 6.92. CONCLUSIONS In a population with cardiovascular risk factors, HDL-cholesterol, Total/HDL-cholesterol and triglycerides/HDL-cholesterol ratios were associated with a higher population attributable risk for cardiovascular disease compared to other common biomarkers.
Collapse
|
131
|
Cordero A, Rodriguez-Manero M, García-Acuña JM, López-Palop R, Cid B, Carrillo P, Agra-Bermejo R, González-Salvado V, Iglesias-Alvarez D, Bertomeu-Martínez V, González-Juanatey JR. Additive value of the CRUSADE score to the GRACE score for mortality risk prediction in patients with acute coronary syndromes. Int J Cardiol 2017; 245:1-5. [DOI: 10.1016/j.ijcard.2017.07.095] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/04/2017] [Revised: 06/09/2017] [Accepted: 07/25/2017] [Indexed: 02/07/2023]
|
132
|
Cordero A, Garcia-Acuna J, Cid B, Rodriguez-Manero M, Lopez-Palop R, Carrillo P, Trillo R, Bertomeu-Martinez V, Gonzalez-Juanatey J. P3302Radial approach reduces hospital mortality in acute coronary syndrome: a propensity score matched study. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx504.p3302] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
133
|
Gunturiz-Beltran C, Lopez Palop R, Carrillo P, Cordero A, Frutos A, Garcia-Carrilero M, Juskova M, Ribes F, Alcantara N, Yepez F. P1397Elderly patients suffer a greater delay in reperfusion by primary percutaneous coronary intervention, mainly due to longer delay until health system contact. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx502.p1397] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
134
|
Rodríguez-Mañero M, Cordero A, Kreidieh O, García-Acuña JM, Seijas J, Agra-Bermejo RM, Abou-Jokh C, Álvarez-Rodríguez L, Álvarez-Iglesias D, López-Palop R, Cid B, Carrillo P, González-Juanatey JR. Proposal of a novel clinical score to predict heart failure incidence in long-term survivors of acute coronary syndromes. Int J Cardiol 2017; 249:301-307. [PMID: 28867245 DOI: 10.1016/j.ijcard.2017.07.084] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/24/2017] [Revised: 06/18/2017] [Accepted: 07/21/2017] [Indexed: 01/03/2023]
Abstract
INTRODUCTION HF remains a frequent complication following MI and adversely affects prognosis. The objective of this study was to identify predictors of HF following MI and to design a risk score for its prediction. METHODS Retrospective study of all consecutive patients admitted for MI. Primary end point was time to incident HF. Patients with previous history of HF were excluded. Death was modelled as competing risk. RESULTS 5737 patients were included. Mean age was 66.32±12.80. During a median follow-up of 47.0months (23.0-73.0), 686 patients (12%) developed HF. Age, diabetes mellitus, peripheral artery disease, renal insufficiency, chronic obstructive pulmonary disease, persistent atrial fibrillation, haemoglobin, troponin peak, diuretic at admission, ventricular function, and revascularization were independent predictors for HF development. According to this multivariate regression analysis, we developed a novel score that allows for the identification of patients at high (≥16), medium (9-15) and low risk (<9) for HF development, with an AUC of 0.77 (IC 95%, 0.76-0.78; p=0.008). CONCLUSIONS Clinical comorbidities were determinant for the development of HF following MI. A simple score effectively categorize patients into low, intermediate, and high-risk. This could be important in order to intensify medical treatment or consider additional interventions.
Collapse
|
135
|
Cordero A, Lopez-Palop R, Moreno-Arribas J, Yepez F, Ribes F, Juskova M, Gunturiz C, Carrillo P, Bertomeu-Gonzalez V, Garcia-Carrilero M, Marco A, Sanchez A, Bertomeu-Martinez V. P1514Predictive value of the INTERHEART-cholesterol score for long-term prognosis of patients with acute coronary syndrome. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx502.p1514] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
136
|
Cordero A, Garcia-Acuna J, Rodriguez-Manero M, Lopez-Palop R, Cid B, Carrillo P, Agra R, Bertomeu-Martinez V, Gonzalez-Juanatey J. P2727Progressive decline in hospital mortality of acute coronary syndrome is mainly driven survival improvement in high-risk patients. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx502.p2727] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
137
|
Cordero A, Lopez-Palop R, Carrillo P, Frutos A, Garcia R, Ribes F, Yepes F, Juskova M, Garcia-Carrilero M, Gunturiz C, Bertomeu-Martinez V. P6078Antiplatelet pre-treatment before emergent revascularization is a major determinant of successful manual thrombectomy. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx493.p6078] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
138
|
Martinez A, Agra Bermejo R, Cordero A, Garcia Acuna J, Alvarez Rodriguez L, Abou-Jokh Casas C, Gomez Otero I, Rodriguez Manero M, Varela Roman A, Cid Alvarez B, Lopez Palop R, Carrillo P, Gonzalez Juanatey J. P3706Prognosis value of new ESC LVEF classification in acute coronary syndrome with and without heart failure. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx504.p3706] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
139
|
Cordero A, Lopez-Palop R, Carrillo P, Ribes F, Marco A, Sanchez A, Juskova M, Yepes F, Alcantara N, Moreno-Arribas J, Quiles J, Bertomeu-Martinez V. P6458Prevalent and incident malignancies in patients admitted for an acute coronary syndrome. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx493.p6458] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
140
|
Cordero A, Lopez-Palop R, Carrillo P, Gunturiz C, Garcia-Carrilero M, Juskova M, Ribes F, Marco A, Sanchez A, Yepez F, Quiles J, Bertomeu-Martinez V. P6448Baseline, new onset and maintained anaemia prognostic value in patients with acute coronary syndrome. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx493.p6448] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
141
|
Lopez-Pineda A, Cordero A, Carratala-Munuera C, Orozco-Beltran D, Bertomeu-Gonzalez V, Quesada J, Gil-Guillen V, Frutos A, Lopez-Palop R, Carrillo P, Bertomeu-Martinez V. P1085Serum hyperuricemia determination improves risk prediction of GRACE score in people with acute coronary syndrome. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx502.p1085] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
142
|
Gunturiz Beltran C, Bertomeu-Gonzalez V, Moreno-Arribas J, Perez L, Martinez-Ferrer J, Alzueta J, Arcocha M, Arenal A, Vinolas X, Alvarez M, Anguera I, Porro R, Castillo-Castillo J, Cordero A, Bertomeu-Martinez V. 3875Discriminators algorithm integrated into implantable defibrillator: diagnostic capacity analysis and impact in the reduction of inappropriate therapies. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx504.3875] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
143
|
Cordero A, López-Palop R, Carrillo P, Frutos A, Gunturiz C, García-Carrilero M, Bertomeu-Martinez V. Initial experience with bioresorbable vascular scaffolds for percutaneous revascularisation in patients with acute coronary syndrome. ACTA ACUST UNITED AC 2017. [DOI: 10.20517/2574-1209.2017.02] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
144
|
Rodriguez Manero M, Alvarez Iglesias D, Lopez-Pardo E, Cordero A, Martinez-Sande JL, Garcia-Seara J, Pena-Gil C, Fernandez-Lopez XA, Varela-Roman A, Gonzalez-Juantey JR. P841Clinical profile and outcomes in octogenarians with atrial fibrillation: a community-based study in a specific European health care area. Europace 2017. [DOI: 10.1093/ehjci/eux151.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
145
|
Gunturiz-Beltran C, Voss U, Iatropoulos D, Miles C, Cordero A, Ernst S. P363Atrial tachyarrhythmia management in commercial airline pilots: do they regain their licence after catheter ablation? Europace 2017. [DOI: 10.1093/ehjci/eux141.089] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
146
|
Gunturiz-Beltrán C, Cordero A, García-Carrilero M, Bertomeu-Martínez V. Pronóstico a largo plazo, reingresos y años potenciales de vida perdidos de los pacientes jóvenes tras un ingreso por insuficiencia cardiaca. Rev Clin Esp 2017; 217:176-178. [DOI: 10.1016/j.rce.2016.11.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2016] [Revised: 10/20/2016] [Accepted: 11/20/2016] [Indexed: 11/29/2022]
|
147
|
Cordero A, Rodriguez Padial L, Batalla A, López Barreiro L, Torres Calvo F, Castellano JM, Ruiz E, Bertomeu-Martínez V. Optimal pharmacological treatment and adherence to medication in secondary prevention of cardiovascular events in Spain: Results from the CAPS study. Cardiovasc Ther 2017; 35. [PMID: 27957818 DOI: 10.1111/1755-5922.12240] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/20/2016] [Revised: 09/26/2016] [Accepted: 12/02/2016] [Indexed: 12/22/2022] Open
Abstract
INTRODUCTION Despite the large amount of evidence supporting the use of antiplatelet agents, beta-blockers, angiotensin antagonists, and lipid-lowering statins in patients with stable coronary artery disease, several studies have documented underprescription of optimal medical treatment (OMT) in Spain. AIMS The present study aimed to describe the current trend of pharmacological prescription in secondary prevention treatment for cardiovascular diseases (CVDs) in a Spanish cohort. METHODS This study was a multicenter, observational, cross-sectional study (CAPS study, FER-CAR-2014-01) in the context of only one visit. Adherence levels to the prescribed medication, the reasons for not prescription of each medication, the existence of possible associations between sociodemographic features, different CVDs, and different drugs with treatment compliance were also analyzed in patients who have suffered cardiovascular effects. RESULTS Six hundred and twelve patients (68.5±10.7 years old; 78% males) were included. OMT was prescribed in 40.8% of the patients. The main reason for not prescribing was due to the physician's discretion. Adherence to medication, measured by the Morisky-Green questionnaire, was 45.8%, and it was positively related to the presence of coronary events (OR 1.80; 95% CI: 1.05-3.21) but not with any drug type. Moreover, a higher educational background implied a higher percentage of adherence to medication. Finally, nonadherent patients were prescribed more daily medicine intakes. CONCLUSIONS Low adherence to guideline-oriented treatment as well as low adherence to medication was found by a self-reported questionnaire. Enhancing adherence to guideline-recommended therapy and reducing treatment complexity seem to be reasonable strategies to improve adherence to secondary prevention medications.
Collapse
|
148
|
Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž, Riccardi G, Taskinen MR, Tokgozoglu L, Monique Verschuren W, Vlachopoulos C, Wood DA, Luis Zamorano J, Cooney MT, Badimon L, Funck-Brentano C, Agewall S, Barón-Esquivias G, Borén J, Bruckert E, Cordero A, Corsini A, Giannuzzi P, Gueyffier F, Krstačić G, Lettino M, Lionis C, Lip GY, Marques-Vidal P, Milicic D, Pedro-Botet J, Piepoli MF, Rigopoulos AG, Ruschitzka F, Tuñón J, von Eckardstein A, Vrablik M, Weiss TW, Williams B, Windecker S, Zimlichman R. Guía ESC/EAS 2016 sobre el tratamiento de las dislipemias. Rev Esp Cardiol 2017. [DOI: 10.1016/j.recesp.2016.11.052] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
149
|
Huanca W, Castro A, Gomez N, Cordero A. 111 BIOCHEMICAL COMPOSITION OF FOLLICULAR FLUID IN RELATION TO THE STIMULUS TO INDUCE OVULATION IN ALPACAS (VICUGNA PACOS). Reprod Fertil Dev 2017. [DOI: 10.1071/rdv29n1ab111] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Alpacas, like other camelids, are induced ovulators. A study was designed to determine the effect of the ovulation-inducing stimulus on the biochemical composition of follicular fluid. Adult female alpacas (n = 18) were examined daily for 3 days by transrectal ultrasonography using a 5-MHz linear-array transducer (Aloka SSD-500, Tokyo, Japan). When the largest growing ovarian follicle was ≥7 mm, alpacas were given 1.0 mL of seminal plasma intramuscularly (SP, n = 9) or 40 µg of busereline acetate intramuscularly (GnRH, n = 9). A transvaginal transducer with an attached needle guide (Aloka UST-945BP-5) was used for collection of follicular fluid 22 h post-induction. Follicular contents were then centrifuged at 800 × g for 20 min to separate the fluid from the cells. The follicular fluid was collected and stored at –20°C until analysis with a semi-automatic biochemical analyzer (SINOWA, China). The results were glucose 49.17 and 47.95 (mg/dL; P > 0.05), total protein 1.85 and 1.15 (g/dL; P < 0.05), albumin 1.11 and 1.13 (g/dL; P > 0.05), triglycerides 3.94 and 3.16 (mg/dL; P > 0.05), cholesterol 39.01 and 42.5 (mg/dL; P > 0.05), phosphatase 32.68 and 21.36 (IU/L; P < 0.05), alanine aminotransferase 3.66 and 5.07 (IU/L; P > 0.05), and lactate dehydrogenase 42.17 and 27.27 (IU/L; P > 0.05) for SP or GnRH treatments, respectively. Results suggest the need to continue research to explain the effect of possible differences in total protein, cholesterol, and phosphatase on oocyte-expressed genes and follicular development.
Research was supported by the project no. 405-PNICP-PIAP-2014-UNMSM.
Collapse
|
150
|
Mateo F, Arenas EJ, Aguilar H, Serra-Musach J, de Garibay GR, Boni J, Maicas M, Du S, Iorio F, Herranz-Ors C, Islam A, Prado X, Llorente A, Petit A, Vidal A, Català I, Soler T, Venturas G, Rojo-Sebastian A, Serra H, Cuadras D, Blanco I, Lozano J, Canals F, Sieuwerts AM, de Weerd V, Look MP, Puertas S, García N, Perkins AS, Bonifaci N, Skowron M, Gómez-Baldó L, Hernández V, Martínez-Aranda A, Martínez-Iniesta M, Serrat X, Cerón J, Brunet J, Barretina MP, Gil M, Falo C, Fernández A, Morilla I, Pernas S, Plà MJ, Andreu X, Seguí MA, Ballester R, Castellà E, Nellist M, Morales S, Valls J, Velasco A, Matias-Guiu X, Figueras A, Sánchez-Mut JV, Sánchez-Céspedes M, Cordero A, Gómez-Miragaya J, Palomero L, Gómez A, Gajewski TF, Cohen EEW, Jesiotr M, Bodnar L, Quintela-Fandino M, López-Bigas N, Valdés-Mas R, Puente XS, Viñals F, Casanovas O, Graupera M, Hernández-Losa J, Ramón Y Cajal S, García-Alonso L, Saez-Rodriguez J, Esteller M, Sierra A, Martín-Martín N, Matheu A, Carracedo A, González-Suárez E, Nanjundan M, Cortés J, Lázaro C, Odero MD, Martens JWM, Moreno-Bueno G, Barcellos-Hoff MH, Villanueva A, Gomis RR, Pujana MA. Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition. Oncogene 2016; 36:2737-2749. [PMID: 27991928 PMCID: PMC5442428 DOI: 10.1038/onc.2016.427] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2016] [Revised: 08/31/2016] [Accepted: 10/10/2016] [Indexed: 01/16/2023]
Abstract
Inhibitors of the mechanistic target of rapamycin (mTOR) are currently used to treat advanced metastatic breast cancer. However, whether an aggressive phenotype is sustained through adaptation or resistance to mTOR inhibition remains unknown. Here, complementary studies in human tumors, cancer models and cell lines reveal transcriptional reprogramming that supports metastasis in response to mTOR inhibition. This cancer feature is driven by EVI1 and SOX9. EVI1 functionally cooperates with and positively regulates SOX9, and promotes the transcriptional upregulation of key mTOR pathway components (REHB and RAPTOR) and of lung metastasis mediators (FSCN1 and SPARC). The expression of EVI1 and SOX9 is associated with stem cell-like and metastasis signatures, and their depletion impairs the metastatic potential of breast cancer cells. These results establish the mechanistic link between resistance to mTOR inhibition and cancer metastatic potential, thus enhancing our understanding of mTOR targeting failure.
Collapse
|